pack bio
Groundbreaking collaboration to unlock the full potential of PacBio’s Onso technology and accelerate breakthrough advances in cancer genomics across Asia
SINGAPORE, Oct. 11, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, high-precision sequencing solutions, today announced a new research collaboration agreement (RCA) with the National Cancer Center. ) has been announced. Singapore Center (NCCS). The partnership aims to accelerate cancer research by leveraging PacBio’s advanced sequencing technologies, including the innovative Onso short-read sequencing platform, to profile the genomic landscape of prevalent cancers in Asia. The purpose is
This research project will focus on profiling prevalent cancers in Asia using PacBio’s Onso short-read sequencing system and Kinnex long-read sequencing kit, with a particular emphasis on single-cell RNA sequencing. The Onso platform is known for its superior accuracy in short-read sequencing, enabling researchers to detect clinically relevant mutations across a variety of cancer types, including gastrointestinal stromal tumors (GIST). Masu. Its unique ability to deliver high-precision data at scale makes it ideal for exploring genomic variations in cancer samples, resulting in robust analyzes that can ultimately provide better cancer diagnosis and treatment. Guaranteed.
As part of the collaboration, DKSH, PacBio’s authorized channel partner in Asia, has installed the Onso platform at NCCS’ Cancer Discovery Hub, dedicated to expanding cancer research and discovery. The results from this collaboration are expected to not only benefit Singapore, but also provide access to this cutting-edge technology to the broader research community in Asia. The collaboration with DKSH strengthens PacBio’s commitment to supporting local researchers in advancing cancer genomics in the region.
Combined with Revio’s long-read sequencing capabilities, this research collaboration will enable scientists to conduct comprehensive multi-omics studies and analyze transcript isoforms and genetic variation at the single-cell level. The integration of Onso for short reads and Revio for long reads ensures a complete and detailed analysis of cancer genomes, offering new possibilities for precision oncology.
Associate Professor Jason Chan, Director of the NCCS Cancer Discovery Hub, said: “We are excited to collaborate with PacBio on this effort, which combines the power of short-read and long-read sequencing to allow us to delve deeper into the complexity of the genome.” Examples of prevalent cancers in Asia. The ultimate goal is to improve diagnostic and treatment options tailored to patients. ”
Jason Kang, general manager and vice president of PacBio APAC, commented: The introduction of the Onso platform, made possible by our trusted partner DKSH, brings our advanced sequencing solutions closer to the research community and enables researchers to gain new insights into cancer biology. ”
For more information, please contact us below.
Contact (PacBio)
Investor:
tod friedman
ir@pacificbiosciences.com
media:
pr@pacificbiosciences.com
About Pack Bio
PacBio (NASDAQ: PACB) is a leading life sciences technology company that designs, develops and manufactures advanced sequencing solutions that help scientists and clinical researchers solve complex genetic problems. Our products and technologies are derived from two highly differentiated core technologies focused on precision, quality and integrity, including HiFi long-read sequencing technology and SBB® short-read sequencing technology. Our products address solutions across a wide range of research applications, including human germline sequencing, animal and plant sciences, infectious diseases and microbiology, oncology, and other emerging applications. For more information, visit www.pacb.com and follow @PacBio.
PacBio products are provided for research use only. Not for use in diagnostic procedures.
Forward-looking statements
This press release may contain “forward-looking statements” within the meaning of the Securities Exchange Act of 1934, as amended, and Section 21E of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking. Statements that include statements regarding the use, scope, benefits, quality or performance of, or the benefits to be obtained or anticipated from the use of, PacBio products or technology, including those related to the RCA between PacBio and NCCS. Unleash the potential of Onso. Accelerating breakthroughs in cancer genomics research. Genomic landscape profiling of prevalent cancers. Detection of clinically relevant mutations. We hope that this collaboration will benefit the research community in Singapore and Asia. Perform comprehensive multi-omics studies using the Revio and Onso platforms to ensure complete and detailed analysis of cancer genomes. and other future events. You should not place undue reliance on forward-looking statements as they involve assumptions, risks and uncertainties that could cause actual outcomes or results to differ materially from those currently anticipated. the difficulty of generating discoveries across different research fields; Potential problems with product performance and quality may occur. third party claims alleging patent and proprietary rights infringement or seeking to invalidate PacBio’s patents or proprietary rights; and other risks associated with international operations. Other factors that could materially affect actual results include PacBio’s most recent filings with the Securities and Exchange Commission, including PacBio’s most recent reports on Forms 8-K, 10-K, and 10-Q; in the filing and includes those listed below the caption. “Risk factors”. These forward-looking statements are based on current expectations and speak only as of the date hereof. Except as required by law, PacBio undertakes no obligation to revise or update these forward-looking statements to reflect future events or circumstances, even if new information becomes available. .
